Naslov
Treatment with two monoclonal antibodies in patient with migraine and relapsing-remitting multiple sclerosis

Autori
Galić, Petra ; Arambašić, Lea ; Miočić, Zara ; Marošević Zubonja, Tea

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Book of abstracts / Pavlović, Vedrana ; Jurić, Ivana ; Prigl, Ivan - Osijek - Osijek, 2022, 71-71

Skup
4th International Translational Medicine Congress of Students and Young Physicians (OSCON 2022)

Mjesto i datum
Osijek, Hrvatska, 31.03.2022. - 02.04.2022

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
Immunomodulatory therapy, Migraine, Multiple sclerosis

Sažetak
INTRODUCTION: Multiple sclerosis (MS) is a potentially progressive autoimmune inflammatory disease of the central nervous system, leading to axon demyelination. When common symptoms of MS are listed, migraine is usually not included. However, some research shows that patients with MS have a higher incidence of certain headaches. CASE REPORT:We present a 48-year-old man with relapsing-remitting MS and migraine. He came to the neurological clinic because of severe headaches and magnetic resonance imaging of the brain was performed, which showed demyelinating lesions. In the coming years, his neurological status worsened. He was several times hospitalized and treated with corticosteroids. Relapsing- remitting MS was set as a diagnosis. He started immunomodulatory therapy of Teriflunomide. Despite treatment, his clinical picture worsened. He was switched to the second-line immunomodulatory therapy of ocrelizumab. The drug is well tolerated with no side effects and no new exacerbations. The patient has also been diagnosed with migraine. He used sumatriptan and analgesics, but with the introduction of immunomodulatory therapy for MS, migraines have become more frequent and intense. The patient was switched to immunomodulatory therapy, which included Erenumab. Headaches are reduced and there was no worsening of neurological status in MS. CONCLUSION: The patient received two monoclonal antibodies simultaneously one in therapy for MS and the other in therapy for migraine. By reviewing all available literature and consulting with companies producing Erenumab and Ocrelizumab did not find any contraindications or interactions when using both drugs at the same time in therapy.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti

POVEZANOST RADA